TUESDAY, Sept. 2 (HealthDay News) -- Contrary to previous study results, the cancer prevention drug anastrozole does not appear to cause impairment of cognitive performance, a new study found.

Anastrozole has been shown to be superior to tamoxifen in preventing breast cancer recurrence in postmenopausal women. But some "cross-sectional" studies have suggested that endocrine therapies such as anastrozole are associated with poorer performance on verbal memory and processing tasks.

TUESDAY, July 29 (HealthDay News) -- The typical U.S. breast cancer screening strategy results in women being tested twice as often as a different approach use in Norway, but both are equally good at detecting disease, a new report says.

WEDNESDAY, July 9 (HealthDay News) -- A third of women who opt for breast-conserving cancer surgery say they now have an asymmetry between their breasts that greatly affects their quality of life, a new study says.

Women whose affected breast looked noticeably different after surgery were twice as likely to fear their cancer returning and to have symptoms of depression when compared with women whose breasts still appeared similar, according to the study by researchers at the University of Michigan Comprehensive Cancer Center.

WEDNESDAY, July 9 (HealthDay News) -- Genetic activity in breast cancer cells from younger patients could explain why tumors tend to more aggressive when they strike at a younger age.

"We haven't had a good reason why younger women do worse than older women," said senior study author Dr. Kimberly Blackwell, director of the clinical trials program in breast cancer at Duke University. "This study offers some insight into why younger women do worse."

THURSDAY, June 26 (HealthDay News) -- Researchers have devised a new breast-imaging technology that appears to be as accurate as MRI scans but several times cheaper.

The technique, called molecular breast imaging (MBI), is still in the early stages of development, the scientists added.

THURSDAY, June 26 (HealthDay News) -- Women with metastatic breast cancer who developed an immune response to an investigational vaccine lived twice as long as those who didn't have an immune response, new research shows.

"If you were an immune responder, you had double the survival of a non-responder," said study author Dr. Susan Domchek, an associate professor of medicine at the University of Pennsylvania.

WEDNESDAY, June 11 (HealthDay News) -- A drug already approved to reduce the risk of breast cancer in high-risk women also seems to cut the risk for other women.

A new analysis finds that those who took raloxifene (Evista) regularly over a number of years were less likely to develop invasive estrogen-receptor (ER) positive breast cancer, compared with women who did not take the drug.

Raloxifene did not, however, cut the risk for noninvasive breast cancer or invasive ER-negative cancers.